Mumbai, August 25, 2021: Fortis Hospital Mulund, the leading multi-specialty tertiary care center is all set to bring forth a new era in Bone Marrow Transplants, with the launch of first-of-its-kind dedicated Bone Marrow Unit in Central Mumbai. The unit was inaugurated by Hon. (IAS) Iqbal Singh Chahal, Commissioner-Municipal Corporation of Greater Mumbai along with Dr. Ashutosh Raghuvanshi, MD & CEO & Dr S Narayani, Zonal Director, Fortis Hospitals Mumbai.
The BMT division headed by Dr. Subhaprakash Sanyal is embedded with state-of-the-art technology and infrastructure which will support the team of clinical experts in treating all kinds of complex hematological diseases. Dr Sanyal, will lead the division along with a dedicated multi-disciplinary team.
Focused on offering superspecialised care for benign and malignant Cancer services for adults and children, Fortis hospital, Mulund remains the preferred Hospital by patients for treatment of all kinds of complex cases related to haematology and haemat-oncology. With progressive expansion of the hospital into a dedicated BMT unit, patients will be provided with the best treatment options which comprises of Congenital Bone Marrow Failure Syndromes, Thalassemia, Sickle Cell Anemia, immunodeficiency disorders, life threatening blood cancers like Multiple Myelomas, Leukemia, and several other forms of advanced tumors.
“Fortis Mulund Hospital is one among very few hospitals to have a specialized Hematology Division. Our team of hematologists have the clinical acumen to diagnose, treat and offer post-treatment care for all blood-related disorders. We understand that Bone Marrow Transplant is a specialised treatment and that such patients need special attention and care. Therefore, we have built the most advanced unit to deliver globally-benchmarked outcomes. I am also thankful to Shri. Iqbal Singh Chahal for supporting the initiative", said Dr S. Narayani, Zonal Director, Fortis Hospitals Mumbai.
Dr Subhaprakash Sanyal, Head-BMT Division, Fortis Hospital, Mulund, said, “Bone Marrow Transplant (BMT) is a well-recognized curative treatment option in the algorithm of many haematological disorders. This treatment requires a well-orchestrated high-end specialty set-up, and a team of highly trained specialists. Without an internationally-benchmarked BMT facility and infrastructure, delivering optimum clinical outcomes becomes difficult. Our new department with six bedded dedicated Bone Marrow Transplant Unit is at par with global standards, in terms of care, expertise, and facilities”.
BMT is a life-saving procedure and is the only way to cure patients diagnosed with Blood Cancer. The process involves taking a patient’s damaged Bone Marrow Stem Cells and replacing them with healthy stem cells from a donor. The procedure can be autologous or allogenic. Autologous transplants use the patient’s own blood cells, while allogenic transplants use cells from a matched donor.
About Fortis Healthcare Limited:
Fortis Healthcare Limited – an IHH Healthcare Berhad Company – is a leading integrated healthcare services provider in India. It is one of the largest healthcare organisations in the country with 36 healthcare facilities (including projects under development), 4000 operational beds and over 400 diagnostics centres (including JVs). Fortis is present in India, United Arab Emirates (UAE) & Sri Lanka. The Company is listed on the BSE Ltd and National Stock Exchange (NSE) of India. It draws strength from its partnership with global major and parent company, IHH, to build upon its culture of world-class patient care and superlative clinical excellence. Fortis employs 23,000 people (including SRL) who share its vision of becoming the world’s most trusted healthcare network. Fortis offers a full spectrum of integrated healthcare services ranging from clinics to quaternary care facilities and a wide range of ancillary services.